Erratum: (2S,1′S,2′R,3′R)-2(2′-Carboxy-3′- hydroxymethylcyclopropyl)glycine-[3H], a potent and selective radioligand for labeling group 2 and 3 metabotropic glutamate receptors (Bioorganic and Medicinal Chemistry Letters (2005) 15 (349) DOI: 10.1016/j.bmcl.2004.10.093);(2S,1′S,2′R,3′R)-2(2′-Carboxy-3′- hydroxymethylcyclopropyl)glycine-[3H], a potent and selective radioligand for labeling group 2 and 3 metabotropic glutamate receptors

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 2, 2005, Pages 349-351

  Wheeler, William J ^a   Clodfelter, Dean K ^a   Kulanthaivel, Palaniappan ^a   Pedregal, Concepcion ^b   Stoddard, Eli A ^a   Wright, Rebecca A ^a   Schoepp, Darryle D ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Avda   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2' CARBOXY 3 HYDROXYMETHYLCYCLOPROPYL)GLYCINE H 3; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 8; RADIOLIGAND; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG; (2S,1'S,2'R,3'R) 2(2' CARBOXY 3' HYDROXYMETHYLCYCLOPROPYL)GLYCINE (3H); (2S,1'S,2'R,3'R)-2(2'-CARBOXY-3'-HYDROXYMETHYLCYCLOPROPYL)GLYCINE-(3H); 2 AMINO 4 PHOSPHONOBUTYRIC ACID; 2-AMINO-4-PHOSPHONOBUTYRIC ACID; AMINOBUTYRIC ACID DERIVATIVE; CYCLOPROPANE DERIVATIVE; DRUG DERIVATIVE; GLUTAMIC ACID; GLYCINE; LIGAND; METABOTROPIC RECEPTOR; TRITIUM;

ARTICLE; BRAIN MEMBRANE; BRAIN TISSUE; CELL CLONING; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; FOREBRAIN; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOLECULAR CLONING; REACTION ANALYSIS; REDUCTION; ANIMAL; BRAIN; CELL LINE; CELL MEMBRANE; CHEMISTRY; DRUG EFFECT; METABOLISM; METHODOLOGY; RAT;

TRITIUM;

AMINOBUTYRIC ACIDS; ANIMALS; BRAIN; CELL LINE; CELL MEMBRANE; CYCLOPROPANES; GLUTAMIC ACID; GLYCINE; HUMANS; ISOTOPE LABELING; LIGANDS; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; TRITIUM;

EID: 10644258619     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.12.054     Document Type: Erratum

References (12)

1. M. Hollmanm, and S. Heinemann Annu. Rev. Neurosci. 17 1994 31
2. P.J. Conn, and P.J. Pin Annu. Rev. Pharmacol. Toxicol. 37 1997 205
3. Y. Nakagawa, K. Saitoh, T. Ishihara, M. Ishida, and H. Shinozaki Eur. J. Pharmacol. 184 1990 205
4. V. Mutel, G. Adam, S. Chaboz, J.A. Kemp, A. Klingelschmidt, J. Messer, J. Wichman, T. Woltering, and J.G. Richards J. Neurochem. 71 1998 2558
5. I. Collado, C. Pedregal, A.B. Bueno, A. Marcos, R. Gonzalez, J. Blanco-Urgoiti, J. Perez-Castells, D.D. Schoepp, R.A. Wright, B.G. Johnson, A.E. Kingston, E.D. Moher, D.W. Hoard, K.I. Griffey, and J.P. Tizzano J. Med. Chem. 47 2004 456
6. All compounds were evaluated by NMR, HPLC, and HR-ES-MS
7. A. Cordova, N.N. Reed, J.A. Ashley, and K.D. Janda Bioorg. Med. Chem. Lett. 9 1999 3119
8. The titration was conducted at Amersham Biosciences, Cardiff, Wales, UK using methods developed by the authors
9. 2O/HOAc
10. HPLC chromatography: Zorbax SB-C18 (4.6 × 250 mm) with gradient elution at 1 mL/min and UV detection at 200 nm as well as radiochemical detection; Solvent A: 2.3 g/L octanesulfonic acid, sodium salt in 0.1% TFA, Solvent B: 0.1% TFA in acetonitrile, Gradient: 3% B for 15 min then to 50% B over 30 min. Radiochemical purity was 92.8%
11. D.D. Schoepp, and R.A. True Neurosci. Lett. 63 1994 938
12. R.A. Wright, J.W. McDonald, and D.D. Schoepp J. Neurochem. 63 1994 938